Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Malignant hyperthermia.

J L Tomarken1, B A Britt

  • 1Emergency Department, University of Toronto, Ontario, Canada.

Annals of Emergency Medicine
|November 1, 1987
PubMed
Summary

Malignant hyperthermia is a serious genetic disorder causing dangerous reactions to anesthesia and stress. Rapid treatment is vital to prevent organ damage and death.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incidence of malignant hyperthermia reactions in 2,214 patients undergoing muscle biopsy.

Canadian journal of anaesthesia = Journal canadien d'anesthesie·1995
Same author

The substitution of Arg for Gly2433 in the human skeletal muscle ryanodine receptor is associated with malignant hyperthermia.

Human molecular genetics·1994
Same author

A mutation in the human ryanodine receptor gene associated with central core disease.

Nature genetics·1993
Same author

Polymorphisms and deduced amino acid substitutions in the coding sequence of the ryanodine receptor (RYR1) gene in individuals with malignant hyperthermia.

Genomics·1992
Same author

The role of the skeletal muscle ryanodine receptor gene in malignant hyperthermia.

Symposia of the Society for Experimental Biology·1992
Same author

A substitution of cysteine for arginine 614 in the ryanodine receptor is potentially causative of human malignant hyperthermia.

Genomics·1991

Area of Science:

  • Anesthesiology
  • Genetics
  • Pharmacology

Background:

  • Malignant hyperthermia (MH) is an inherited pharmacogenetic disorder.
  • It presents as a hypermetabolic crisis triggered by specific anesthetic agents and succinylcholine.
  • MH can also be exacerbated by physical or emotional stress.

Purpose of the Study:

  • To define the characteristics of malignant hyperthermia.
  • To emphasize the critical need for prompt and effective patient management.
  • To highlight the potential for severe consequences if treatment is delayed.

Main Methods:

  • Review of existing literature on malignant hyperthermia.
  • Analysis of clinical case studies and outcomes.
  • Identification of key triggers and diagnostic criteria.

Main Results:

  • Malignant hyperthermia involves rapid muscle breakdown and extreme temperature elevation.
  • Delayed intervention correlates with increased risk of mortality and organ damage.
  • Early recognition and specific treatments (e.g., dantrolene) are crucial.

Conclusions:

  • Malignant hyperthermia requires immediate medical intervention.
  • Effective management protocols are essential for patient survival.
  • Understanding MH triggers is key for anesthetic safety and patient outcomes.

Related Experiment Videos